...
首页> 外文期刊>International journal of antimicrobial agents >Bloodstream infections in cancer patients with febrile neutropenia
【24h】

Bloodstream infections in cancer patients with febrile neutropenia

机译:发热性中性粒细胞减少症癌症患者的血流感染

获取原文
获取原文并翻译 | 示例

摘要

Bloodstream infections (bacteraemia) account for approximately 25-30% of febrile episodes in patients with febrile neutropenia (FN). In developed countries, Gram-positive pathogens predominate. Mortality is higher in Gram-negative bacteraemia. A recent study involving 2142 patients with FN was reviewed, including 168 patients with Gram-negative bacteraemia (mortality 18%), 283 patients with Gram-positive bacteraemia (mortality 5%) and 48 patients with polymicrobial bacteraemia (mortality 13%). Among patients who received prophylactic antibiotics, Gram-positive bacteraemia was far more common than Gram-negative bacteraemia (75% vs. 25%), compared with approximately 50% of each in patients without prophylactic antibiotics. Patients with a Multinational Association for Supportive Care in Cancer (MASCC) score < 15 had a 36% mortality compared with 3% if the MASCC score was > 21. The MASCC score may help risk strati. cation of patients with FN and bacteraemia, although these data require confirmation. In two series of patients from developing countries (Lebanon and Malaysia), Gram-negative bacteraemia was more common and mortality was higher. In developing countries, Gram-negative bacteraemia may be more frequent due to less use of prophylactic antibiotics and central lines. Laboratory markers may have predictive and prognostic value for bacteraemia in patients at the onset of FN, including mannose-binding lectin, interleukin (IL)-6, IL-8 and procalcitonin, but further studies are required before they can be recommended. New therapies are required to lower the mortality in patients with FN with a high risk for bacteraemia. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
机译:发热性中性粒细胞减少症(FN)患者的发热发作中,血流感染(菌血症)约占25-30%。在发达国家,革兰氏阳性病原体占主导地位。革兰氏阴性菌血症的死亡率较高。回顾了一项最近的研究,涉及2142例FN患者,包括168例革兰氏阴性菌血症(死亡率18%),283例革兰氏阳性菌血症(死亡率5%)和48例多菌种细菌血症(死亡率13%)。在接受预防性抗生素治疗的患者中,革兰氏阳性菌血症比革兰氏阴性菌血症更为普遍(75%比25%),而没有预防性抗生素的患者中,每人约占50%。多国癌症支持护理协会(MASCC)得分<15的患者具有36%的死亡率,而如果MASCC得分> 21,则其死亡率为3%。MASCC得分可能有助于分层风险。 FN和菌血症患者的阳离子,尽管这些数据需要确认。在来自发展中国家(黎巴嫩和马来西亚)的两个系列患者中,革兰氏阴性菌血症更为常见,死亡率更高。在发展中国家,由于较少使用预防性抗生素和中心线,革兰氏阴性菌血症可能更常见。 FN发作时实验室标记物可能对细菌血症具有预测和预后价值,包括甘露糖结合凝集素,白介素(IL)-6,IL-8和降钙素,但在推荐之前还需要进一步研究。需要新的疗法来降低具有菌血症高风险的FN患者的死亡率。 (c)2008年Elsevier B.V.和国际化学疗法学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号